---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-026142"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:11:25.766167+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TELA Bio reports Q4 revenue $17.6M (+4% YoY); guides FY2025 revenue $85-88M (+23-27%)

## Summary
- FY2024 revenue $69.3M (+19% YoY); Q4 revenue $17.6M (+4% YoY) missed expectations due to transient disruptions.
- FY2024 net loss narrowed to $37.8M from $46.7M in 2023; Q4 net loss $9.2M vs $12.9M a year ago.
- FY2025 revenue guidance $85-88M (23-27% growth); Q1 2025 revenue expected $17-18M (2-8% growth).
- Operating expenses step down Q3 to Q4; management targets 2025 OpEx flat vs 2024.
- OviTex IHR product for inguinal hernia repair launched mid-April 2024, sold over 1,200 units in 2024.

## SEC filing metadata
- accession: 0001104659-25-026142
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465925026142/0001104659-25-026142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465925026142/tm259858d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-026142
- JSON: https://secwatch.observer/filing/0001104659-25-026142.json
- Plain text: https://secwatch.observer/filing/0001104659-25-026142.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.